RobertRisingerMD
Psychiatry • New Haven, CTChild & Adolescent Psychiatry, Neuropsychiatry, Psychopharmacology, Clinical Pharmacology
Physician
Dr. Risinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
BioXcel Therapeutics
555 Long Wharf Drive
New Haven, CT 06511- Is this information wrong?
Summary
- Dr. Robert Risinger is a psychiatrist in New Haven, CT. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 29 years. He specializes in child & adolescent psychiatry, neuropsychiatry, psychopharmacology, and clinical pharmacology and is experienced in learning disorders and attention-deficit/hyperactivity disorder.
Education & Training
National Institutes of Health Clinical CenterResidency, Psychiatry, 1991 - 1994
Emory University School of MedicineResidency, Psychiatry, 1988 - 1991
University of Pittsburgh School of MedicineClass of 1988
Certifications & Licensure
WI State Medical License 1997 - 2025
Clinical Trials
- A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Start of enrollment: 2015 Dec 01
- A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Start of enrollment: 2015 Dec 01
- Sequential Therapy for the Treatment of Severe Bipolar Depression. Start of enrollment: 2018 Jan 15
- Join now to see all
Publications & Presentations
PubMed
- Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.Jermaine D Jones, Lavanya Rajachandran, Frank Yocca, Robert Risinger, Michael De Vivo, Jeff Sabados, Frances R Levin, Sandra D Comer> ;The American Journal of Drug and Alcohol Abuse. 2023 Jan 2
- Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed...Leslie Citrome, Robert Risinger, Lavanya Rajachandran, Heather Robison> ;Advances in Therapy. 2023 Jan 1
- 7 citationsSublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.Leslie Citrome, Sheldon H Preskorn, John Lauriello, John H Krystal, Rishi Kakar, Jeffrey Finman, Michael De Vivo, Frank D Yocca, Robert Risinger, Lavanya Rajachandran> ;The Journal of Clinical Psychiatry. 2022 Oct 3
- Join now to see all
Press Mentions
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for at-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaMay 25th, 2023- Edited Transcript of BTAI.OQ Earnings Conference Call or Presentation 14-Aug-20 12:30pm GMTAugust 14th, 2020
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy TrialJune 10th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
